Initially formed as a shell company with seed financing in 2018, a year later ArsenalBio has emerged with an $85 million Series A round to finance its development of cell therapies for cancer.
“Founded to discover, develop and commercialize curative immune cell therapies,” The San Francisco-based biotech firm has caught the attention of investors for a little more than their innovative flair...
Sorry, you need to subscribe to read this article.
If you would like to access this article, please subscribe below.
Premium subscribers receive complete access to our site content which includes market research and insights as well as coverage of the most important news, issues and events related to the healthcare technology industry.